Abstract
Background: The efficacy and biosafety of a previously established tolerable dosage of doxorubicin have not been established in horses. Objectives: To provide preliminary evidence of the efficacy of doxorubicin in tumor-bearing horses, explore drug pharmacokinetics profile, and estimate period of risk of exposure to drug residues. Animals: Twelve horses with 37 tumors. Procedures: Treatment protocol included 6 treatments at 3-week intervals. Eight horses were uniformly treated at a dosage of 70 mg/m2 and 4 horses received 4 of 6 treatment cycles at 70 mg/m2. Clinical signs, tumor responses, and toxicoses were evaluat Drug residue concentrations were quantitated in 3 horses receiving of 65, 70, and 75 mg/m2 by high-performance liquid chromatography with ultraviolet detection (plasma, feces) and liquid chromatography and tandem mass spectrometry (urine). Results: Thirty tumors, including lymphomas, carcinomas, sarcoids, and melanoma, were evaluated for efficacy. The overall response rate was 47% (95% CI, 28-65%). Doxorubicin was not found to be effective against melanomas. Lymphomas and carcinomas were most responsive. Pooled serum Cmax and half-life of doxorubicin were 121.3 ng/mL and 12.9 hours, respectively. There were no detectable residues in fecal samples up to 3 weeks after treatment and in plasma and urine after 2 and 3 days, respectively. Conclusion and Clinical Relevance: This study provides preliminary evidence that single-agent doxorubicin at a dosage of 70 mg/m2 has a broad spectrum of activity. The risk of exposure to drug residues in plasma and feces was low. Direct contact with urine-contaminated wastes should be avoided for 2 days after treatment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1581-1588 |
| Number of pages | 8 |
| Journal | Journal of Veterinary Internal Medicine |
| Volume | 27 |
| Issue number | 6 |
| DOIs | |
| State | Published - Nov 2013 |
Fingerprint
Keywords
- Chemotherapy
- Doxorubicin
- Equine
- Oncology
ASJC Scopus subject areas
- veterinary(all)
Cite this
A pilot phase II study of the efficacy and biosafety of doxorubicin chemotherapy in tumor-bearing equidae. / Theon, Alain P; Pusterla, Nicola; Magdesian, K G; Wittenburg, Luke Anthony; Marmulak, T.; Wilson, William D.
In: Journal of Veterinary Internal Medicine, Vol. 27, No. 6, 11.2013, p. 1581-1588.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A pilot phase II study of the efficacy and biosafety of doxorubicin chemotherapy in tumor-bearing equidae
AU - Theon, Alain P
AU - Pusterla, Nicola
AU - Magdesian, K G
AU - Wittenburg, Luke Anthony
AU - Marmulak, T.
AU - Wilson, William D
PY - 2013/11
Y1 - 2013/11
N2 - Background: The efficacy and biosafety of a previously established tolerable dosage of doxorubicin have not been established in horses. Objectives: To provide preliminary evidence of the efficacy of doxorubicin in tumor-bearing horses, explore drug pharmacokinetics profile, and estimate period of risk of exposure to drug residues. Animals: Twelve horses with 37 tumors. Procedures: Treatment protocol included 6 treatments at 3-week intervals. Eight horses were uniformly treated at a dosage of 70 mg/m2 and 4 horses received 4 of 6 treatment cycles at 70 mg/m2. Clinical signs, tumor responses, and toxicoses were evaluat Drug residue concentrations were quantitated in 3 horses receiving of 65, 70, and 75 mg/m2 by high-performance liquid chromatography with ultraviolet detection (plasma, feces) and liquid chromatography and tandem mass spectrometry (urine). Results: Thirty tumors, including lymphomas, carcinomas, sarcoids, and melanoma, were evaluated for efficacy. The overall response rate was 47% (95% CI, 28-65%). Doxorubicin was not found to be effective against melanomas. Lymphomas and carcinomas were most responsive. Pooled serum Cmax and half-life of doxorubicin were 121.3 ng/mL and 12.9 hours, respectively. There were no detectable residues in fecal samples up to 3 weeks after treatment and in plasma and urine after 2 and 3 days, respectively. Conclusion and Clinical Relevance: This study provides preliminary evidence that single-agent doxorubicin at a dosage of 70 mg/m2 has a broad spectrum of activity. The risk of exposure to drug residues in plasma and feces was low. Direct contact with urine-contaminated wastes should be avoided for 2 days after treatment.
AB - Background: The efficacy and biosafety of a previously established tolerable dosage of doxorubicin have not been established in horses. Objectives: To provide preliminary evidence of the efficacy of doxorubicin in tumor-bearing horses, explore drug pharmacokinetics profile, and estimate period of risk of exposure to drug residues. Animals: Twelve horses with 37 tumors. Procedures: Treatment protocol included 6 treatments at 3-week intervals. Eight horses were uniformly treated at a dosage of 70 mg/m2 and 4 horses received 4 of 6 treatment cycles at 70 mg/m2. Clinical signs, tumor responses, and toxicoses were evaluat Drug residue concentrations were quantitated in 3 horses receiving of 65, 70, and 75 mg/m2 by high-performance liquid chromatography with ultraviolet detection (plasma, feces) and liquid chromatography and tandem mass spectrometry (urine). Results: Thirty tumors, including lymphomas, carcinomas, sarcoids, and melanoma, were evaluated for efficacy. The overall response rate was 47% (95% CI, 28-65%). Doxorubicin was not found to be effective against melanomas. Lymphomas and carcinomas were most responsive. Pooled serum Cmax and half-life of doxorubicin were 121.3 ng/mL and 12.9 hours, respectively. There were no detectable residues in fecal samples up to 3 weeks after treatment and in plasma and urine after 2 and 3 days, respectively. Conclusion and Clinical Relevance: This study provides preliminary evidence that single-agent doxorubicin at a dosage of 70 mg/m2 has a broad spectrum of activity. The risk of exposure to drug residues in plasma and feces was low. Direct contact with urine-contaminated wastes should be avoided for 2 days after treatment.
KW - Chemotherapy
KW - Doxorubicin
KW - Equine
KW - Oncology
UR - http://www.scopus.com/inward/record.url?scp=84887616095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887616095&partnerID=8YFLogxK
U2 - 10.1111/jvim.12144
DO - 10.1111/jvim.12144
M3 - Article
C2 - 24107145
AN - SCOPUS:84887616095
VL - 27
SP - 1581
EP - 1588
JO - Journal of Veterinary Internal Medicine
JF - Journal of Veterinary Internal Medicine
SN - 0891-6640
IS - 6
ER -